Nature Search

Enhanced antibody half-life improves in vivo activity

A correlation between drug exposure and efficacy has never been demonstrated for therapeutic antibodies. Zalevsky et al. use a humanized mouse model to show that a reduction in antibody clearance engineered through increased antibody affinity for the neonatal Fc receptor enhances antitumor activity.

Jonathan Zalevsky
Aaron K Chamberlain
John R Desjarlais
Research17 Jan 2010
Nature Biotechnology

Volume: 28, P: 157-159
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials

Impaired interleukin-2 production and regulatory T cell dysfunction is implicated in multiple autoimmune diseases. Here, in two phase lb trials, the authors show that rezpegaldesleukin, a Treg-selective pegylated IL-2, is safe and improves symptoms in patients with atopic dermatitis or psoriasis.

Jonathan I. Silverberg
David Rosmarin
Jonathan Zalevsky
ResearchOpen Access25 Oct 2024
Nature Communications

Volume: 15, P: 1-19
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

Adoptive cell transfer (ACT) of T cells for tumor treatment often requires IL-2 administration. Here, the authors show that a modified IL-2 cytokine (NKTR-214) can outperform IL-2 in a melanoma mouse model.

Giulia Parisi
Justin D. Saco
Antoni Ribas
ResearchOpen Access31 Jan 2020
Nature Communications

Volume: 11, P: 1-12
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Interleukin-2 can induce an anti-tumour response, but is associated with toxicity. Here, the authors demonstrate that an engineered interleukin-2 promotes intratumoral T regulatory cell depletion while enhancing effective anti-tumour CD8⁺ T cell responses that result in potent tumor suppression.

Meenu Sharma
Hiep Khong
Willem W. Overwijk
ResearchOpen Access31 Jan 2020
Nature Communications

Volume: 11, P: 1-11

Quick links

Search

Filter By:

Enhanced antibody half-life improves in vivo activity

The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Search

Quick links